The Exelixis Inc (EXEL) share price is expected to increase by 27.32% over the next year. This is based on calculating the average 12-month share price estimate provided by 16 stock analysts who have covered EXEL. Price targets range from $18.00 at the low end to $31.00 at the high end. The current analyst consensus for EXEL is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 16 Wall Street analysts have assignedEXEL 13 buy ratings, 2 hold ratings, and 1 sell ratings. This means that analysts expect Exelixis Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EXEL. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
jay olson Oppenheimer | Buy | $29.0 | maintained | Feb 8, 2024 |
yaron werber TD Cowen | Buy | $25.0 | maintained | Feb 7, 2024 |
chris shibutani Goldman Sachs | Sell | $18.0 | maintained | Feb 7, 2024 |
gregory renza RBC Capital | Buy | $28.0 | reiterated | Feb 7, 2024 |
joseph catanzaro Piper Sandler | Buy | $28.0 | reiterated | Feb 7, 2024 |
christopher liu Leerink Partners | Hold | $19.0 | reiterated | Feb 7, 2024 |
robert burns H.C. Wainwright | Buy | $28.0 | reiterated | Feb 7, 2024 |
etzer darout BMO Capital | Buy | $29.0 | maintained | Feb 6, 2024 |
peter lawson Barclays | Buy | $25.0 | maintained | Feb 6, 2024 |
david lebovitz Citi | Buy | $31.0 | maintained | Feb 6, 2024 |
akash tewari Jefferies | Buy | $30.0 | maintained | Jan 25, 2024 |
kaveri pohlman BTIG | Buy | $27.0 | rated | Jan 25, 2024 |
silvan tuerkcan JMP Securities | Buy | $27.0 | reiterated | Jan 19, 2024 |
derek archila Wells Fargo | Buy | $28.0 | maintained | Jan 17, 2024 |
stephen willey Stifel Nicolaus | Hold | $23.0 | maintained | Jan 8, 2024 |
jason gerberry Bank of America Securities | Buy | $27.0 | maintained | Dec 12, 2023 |
jeffrey hung Morgan Stanley | Hold | $23.0 | maintained | Nov 2, 2023 |
michael schmidt Guggenheim | Buy | $30.0 | maintained | Sep 25, 2023 |
asthika goonewardene Truist Financial | Buy | $32.0 | maintained | Aug 2, 2023 |
michael king EF Hutton | Buy | $24.0 | reiterated | Apr 28, 2023 |
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
When did it IPO
2000
Staff Count
1,310
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Michael M. Morrissey Ph.D.
Market Cap
$6.25B
In 2023, EXEL generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EXEL's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2019
Revenue From 2020
Revenue From 2021
Revenue From 2022
BBIO-USD
$33.6
FRSH-USD
$20.33
$85.63
LFUS-USD
$247.13
IONS-USD
$44.35
BPOP-USD
$83.48